decis expect
februari patent trial appeal board ptab deni
ipr tecfidera expect
appeal decis histor odd high
like win appeal
notic appeal file notic appeal ptab
indic appeal tecfidera ipr decis ptab
issu decis involv key patent protect tecfidera
 patent discuss ipr decis implic
prior note note notic appeal formal document
initi appeal contain substanc argument
step feder circuit appeal court docket appeal
occur day day file appeal brief
may ask court extens file brief
file repli brief afterward feder circuit schedul oral
hear typic issu decis around month oral hear
time appeal decis feder circuit appeal court took averag
month finish appeal ipr decis expect
affect time feder circuit take finish appeal
appeal mostli base written submiss oral argument
done remot explain prior note may slow boat
appeal exampl file multipl extens appeal ipr
decis later join appeal decis two tecfidera
district court case like provid sometim
odd high like win appeal although
better sens odd appeal file appeal brief
note feder circuit affirm ipr decis
author materi act capac attorney
hold materi intend either legal opinion
legal advic inform provid herein provid possibl
outcom probabl outcom result legal disput
controversi depend varieti factor includ limit
parti histor relationship law pertain case rel litig talent
trial locat juri composit judg composit investor contact
legal advisor issu law relat subject matter
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
valuat methodolog risk
main driver tecfidera spinraza ocrevu pipelin
risk upsid
aducanumab approv strong sale
spinraza competitor fail make market
pipelin success stroke pain follow-on multipl sclerosi compound
risk downsid
aducanumab approv
rituxan biosimilar take share quickli ocrevu lose share ofatumumab
pt base upon stand-alon ebitda estim ev
stand-alon ebitda net debt yield equiti
valu share price base share valuat low end
rang given uncertain growth prospect
risk upsid
result forecast corpor action benefit multipl expect
improv govern prospect benefit share price fix overhang lift
risk downsid
result and/or guidanc could fall short expect corpor action could
disappoint on-going us price fix investig may result fine
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report matthew
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import regulatori disclosur subject compani
analyst strategist household member identifi own follow secur relat deriv thoma laveri amgen inc
common prefer stock
februari benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur alector inc amgen inc aprea
within last month receiv compens invest bank servic alector inc
next month expect receiv intend seek compens invest bank servic akebia
within last month receiv compens product servic invest bank servic amgen inc
within last month provid provid invest bank servic invest bank client relationship
follow compani alector inc amgen inc
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani amgen inc beigen ltd biogen inc biomarin
 co llc make market secur alector inc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
use rel rate system use term overweight equal-weight not-rat underweight see definit morgan
stanley assign rate buy hold sell stock cover overweight equal-weight not-rat underweight equival
buy hold sell investor care read definit rate use morgan stanley research addit sinc morgan stanley research
contain complet inform concern analyst view investor care read morgan stanley research entireti infer
content rate alon case rate research use reli upon invest advic investor decis buy sell
stock depend individu circumst investor exist hold consider
march
stock rate describ appli fundament equiti research appli debt research produc firm
disclosur purpos accord finra requir includ categori head buy hold sell alongsid rate
overweight equal-weight not-rat underweight assign rate buy hold sell stock cover overweight
equal-weight not-rat underweight equival buy hold sell repres recommend rel weight see definit
satisfi regulatori requir correspond overweight posit stock rate buy recommend correspond equal-weight
not-rat hold underweight sell recommend respect
data includ common stock adr current assign rate invest bank client compani receiv invest
bank compens last month due round decim percentag provid total column may add exactli
overweight stock total return expect exceed averag total return analyst industri industri team coverag univers
risk-adjust basi next month
equal-weight stock total return expect line averag total return analyst industri industri team coverag univers
risk-adjust basi next month
not-rat nr current analyst adequ convict stock total return rel averag total return analyst
industri industri team coverag univers risk-adjust basi next month
underweight stock total return expect averag total return analyst industri industri team coverag univers
risk-adjust basi next month
unless otherwis specifi time frame price target includ morgan stanley research month
attract analyst expect perform industri coverag univers next month attract vs relev broad
market benchmark indic
in-lin analyst expect perform industri coverag univers next month line relev broad market
benchmark indic
cautiou analyst view perform industri coverag univers next month caution vs relev broad market
benchmark indic
benchmark region follow north america latin america relev countri index latin america index europ
europ japan topix asia relev countri index sub-region index ac asia pacif ex japan index
stock price price target rate histori rate definit
import disclosur morgan stanley smith barney llc custom
